Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report

Figure 3 After 3 cycles of pembrolizumab, contrast-enhanced neck and chest computed tomography and evaluation after 4^th chemotherapy. A, C, E: Evaluation after 4^th chemotherapy; B, D, and F: After 3 cycles of pembrolizumab, contrast-enhanced neck and chest computed tomography shows the markedly decreased size of metastatic lymphadenopathy on both cervical level II to V, enhanced nodule in anterior segment of left upper lobe, and mass in left 7^th rib compared with response evaluation after 4^th chemotherapy.